Cadila Healthcare gained 1.73% to Rs 266.80 after the company launched affordable oral anti-diabetic tablet Vinglyn in India.
The company on Wednesday said it has launched an affordable oral anti-diabetic agent, Vinglyn (Vildagliptin) & Vinglyn M (Vildagliptin plus metlorrnin). The drug belongs to the class of oral anti-diabetic agents, known as DPP4 inhibitors, which have shown promise in achieving glycaernie control without deterioration in beta cell function and are one of the recent advancements in diabetes care and management.
Vinglyn and Vinglyn M will be marketed by Zydus Healthcare. Priced at just Rs 4.95 per tablet, which is almost 1/6th the price at which the patented Vildagliptin was initially launched in India, Vinglyn is now one of the most affordable brands of Vildagliptin for diabetic patients in India.
Cadila Healthcare has gained 15.87% in one month as compared to a 3.03% rise in Nifty Pharma index.
Cadila Healthcare’s consolidated net profit slumped 34.1% to Rs 303.60 crore on 23% rise in net sales to Rs 3,406.20 crore in Q1 June 2019 over Q1 June 2018.
Cadila Healthcare is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.-Business Standard